Among these, refractory seizures are particularly prevalent, affecting up to 70-90% of patients with low-grade gliomas due to the epileptogenic effects of the IDH mutation-driven oncometabolite 2-hydroxyglutarate (2-HG). This evidence concerns the gene IDH2 and central nervous system cancer.